Division of Prevention and Community Health, National Center for Cardiovascular Disease, National Clinical Research Center of Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, 47885Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Department of Epidemiology, 569172School of Medicine, Jinan University, Guangzhou, China.
Diab Vasc Dis Res. 2021 Oct-Dec;18(6):14791641211067416. doi: 10.1177/14791641211067416.
The epidemiological data on the use of aspirin in diabetic patients is very limited. The main purpose of this study is to examine the current status of aspirin use in the United States (US) and China in large representative populations.
Data came from the National Health and Nutrition Examination Survey (NHANES) and China Hypertension Survey (CHS), two nationally representative cross-sectional studies.
The percentage of aspirin use was 73.8% in US diabetic patients with ASCVD, and the percentage of aspirin use in diabetic patients with high ASCVD risk was marginally higher in men ( = .052), 54.5% in men and 37.1% in women. The percentages of aspirin use in diabetic patients with intermediate and low ASCVD risk were 55.1% and 35.0%, respectively. In China, the percentage of aspirin use in diabetic patients with ASCVD was 53.5%, and were 14.3%, 9.7%, and 3.2% among diabetic patients with high, intermediate, and low ASCVD risk, respectively.
In summary, the percentage of aspirin use in primary prevention in US diabetic patients in men was higher than in women, and this percentage for primary and secondary prevention in US patients was higher than that in Chinese patients.
关于糖尿病患者使用阿司匹林的流行病学数据非常有限。本研究的主要目的是在美国（美国）和中国的大型代表性人群中检查阿司匹林的使用现状。
数据来自全国健康和营养检查调查（NHANES）和中国高血压调查（CHS），这两项全国代表性的横断面研究。
美国 ASCVD 糖尿病患者中阿司匹林使用率为 73.8%，高 ASCVD 风险糖尿病患者中男性使用阿司匹林的比例略高（ =.052%），男性为 54.5%，女性为 37.1%。中低 ASCVD 风险糖尿病患者的阿司匹林使用率分别为 55.1%和 35.0%。在中国，ASCVD 糖尿病患者中阿司匹林的使用率为 53.5%，高、中、低 ASCVD 风险的糖尿病患者分别为 14.3%、9.7%和 3.2%。
总之，美国男性糖尿病患者一级预防中阿司匹林使用率高于女性，美国患者一级和二级预防中阿司匹林使用率高于中国患者。
